Analysis of S100A12 plasma levels in hyperlipidemic subjects with or without familial hypercholesterolemia

AimsInflammation is a key regulatory process that links hypercholesterolemia and immune mechanisms promoting atherosclerosis. Inflammatory biomarkers may be helpful to better define the atherosclerotic burden in patients with high cholesterol levels such as familial hypercholesterolemia (FH). Our aim was to evaluate the concentration of S100A12 protein in FH patients and its association with pulse wave velocity (PWV).MethodsWe measured glucose and lipid profile, S100A12, sRAGE, esRAGE and PWV in 39 patients with a genetically confirmed diagnosis of FH and 39 hypercholesterolemic subjects without a clinical diagnosis of FH (Dutch score3). All subjects were on statin treatment at the time of the enrollment.ResultsNo difference of glucose and lipid profile was found in the two groups. FH patients had higher S100A12 plasma levels than non-FH subjects (12.874.82 vs. 8.57 +/- 4.87ng/mL, p<0.01). No difference of hs-CRP, sRAGE and esRAGE was found between the two groups. Also, PWV was higher in FH patients than non-FH subjects (8.63 +/- 0.92 vs. 6.68 +/- 0.73m/s, p<0.05). Finally, S100A12 was independently correlated with age (p<0.01), genetic mutation (p<0.01) and PWV (p<0.001).Conclusions FH patients exhibited higher S100A12 levels than non-FH subjects. A novel vascular inflammation pathway, other than hs-CRP, might be useful to better characterize cardiovascular risk profile.